12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Letermovir: Phase II data

A double-blind, U.S. and German Phase II trial in 133 CMV-seropositive allogeneic HBPC transplant recipients showed that once-daily 120 and 240 mg oral letermovir each met the co-primary endpoint of reducing the incidence of CMV prophylaxis failure, defined as development of systemic detectable CMV replication (viral load >42 DNA copies/mL) or CMV...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >